Cegedim S.A. has entered a definitive merger agreement to acquire Dendrite International, Inc. for approximately $751 million in cash. The acquisition combines Cegedim’s European strength with Dendrite’s U.S. and Asia Pacific position, expanding sales, marketing, clinical and compliance solutions offered to the global life sciences and pharmaceutical industry. The combined company is expected to have estimated annual revenues of $1.1 billion and operate in more than 75 countries throughout Europe, the Americas and Asia Pacific.

Jean-Claude Labrune, founder, chairman and chief executive officer of Cegedim, said, “We are very excited to join forces with Dendrite’s talented team to create a truly global business with increased international reach, a broader scope of product offerings and the strength to invest in the development of innovative technologies. As a combined organization we can achieve an even higher quality of service and will be better able to serve our clients in our competitive global marketplace.”

Edward J. Kfoury, lead independent director on Dendrite’s board, said, “Following an extensive and thorough review process, in which we considered a number of alternatives, including interest from various strategic and financial third parties, the board believes that the offer from Cegedim maximizes value for Dendrite’s shareholders.”

The merger, subject to the approval of Dendrite shareholders and other customary closing conditions, is expected to close within the next few months.